Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9501.026 | 0.7942 | 0.4779 | 0.7616 | |
| LY2 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 10264.026 | 1.0349 | 1.0461 | 1.5047 | |
| LY2 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 10264.026 | 0.9641 | 0.9520 | 1.5047 | |
| LY2 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 10264.026 | 1.0621 | 1.0817 | 1.5047 | |
| LY2 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 10264.026 | 0.9387 | 0.9177 | 1.5047 | |
| LY2 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 10264.026 | 0.9954 | 0.9938 | 1.5047 | |
| LY2 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 10264.026 | 0.9998 | 0.9998 | 1.5047 | |
| LY2 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 10264.026 | 0.9879 | 0.9839 | 1.5047 | |
| LY2 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 10264.026 | 0.9738 | 0.9650 | 1.5047 | |
| LY2 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 10264.026 | 0.8925 | 0.8544 | 1.5047 | |
| MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9551.026 | 1.0411 | 1.0307 | 2.6508 | |
| MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9551.026 | 0.9839 | 0.9878 | 2.6508 | |
| MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9551.026 | 1.0697 | 1.0515 | 2.6508 | |
| MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9551.026 | 0.9743 | 0.9805 | 2.6508 | |
| MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9551.026 | 1.0509 | 1.0378 | 2.6508 | |
| MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9551.026 | 0.9888 | 0.9915 | 2.6508 | |
| MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9551.026 | 1.0913 | 1.0670 | 2.6508 | |
| MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9551.026 | 1.0266 | 1.0199 | 2.6508 | |
| MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9551.026 | 0.8881 | 0.9124 | 2.6508 | |
| MCF 10F | NM | - | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 7487.102 | 0.9772 | 0.9700 | 1.5273 | |
| MCF 10F | NM | - | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 7487.102 | 0.9905 | 0.9875 | 1.5273 | |
| MCF 10F | NM | - | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 7487.102 | 0.9764 | 0.9689 | 1.5273 | |
| MCF 10F | NM | - | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 7487.102 | 0.9884 | 0.9848 | 1.5273 | |
| MCF 10F | NM | - | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 7487.102 | 0.9578 | 0.9443 | 1.5273 | |
| MCF 10F | NM | - | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 7487.102 | 0.9686 | 0.9587 | 1.5273 |